Novel Anti-Platelet Drug AT-10 Shows Promise in Overcoming Clopidogrel Resistance
• A Phase 1 study demonstrates that AT-10, a novel anti-platelet agent, effectively overcomes the genetic limitations of clopidogrel in both poor and extensive metabolizers of CYP2C19.
• AT-10 achieved significantly higher platelet inhibition compared to clopidogrel across all patient groups, with superior pharmacokinetic profiles in both single and multiple dose regimens.
• The drug showed a favorable safety profile with minor adverse events, potentially offering a more reliable alternative to clopidogrel for patients with cardiovascular conditions.
© Copyright 2025. All Rights Reserved by MedPath